secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corvus Pharmaceuticals, Inc. (CRVS)
CIK:        0001626971
Form:       8-K
Filed at:   2025-04-09T23:59:59+00:00
Accession:  0001171843-25-002110
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Corvus Pharmaceuticals appoints Richard van den Broek to Board, effective April 8, 2025
--------------------------------------------------------------------------------

- Richard van den Broek appointed as Class II director, term expiring at 2027 annual meeting.
- Appointed to Audit Committee ($10k annual) and Nominating Committee ($4k annual) effective April 8, 2025.
- Will receive $35k annual board retainer, prorated for current quarter, plus initial option for 30,000 shares.
- Will enter into standard indemnification agreement for directors and officers.
- Compensation consistent with company's non-employee director compensation program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626971/000117184325002110/0001171843-25-002110-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626971/000117184325002110/f8k_040825.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-002110

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer